Comparison of 3 L-α-acetyl-methadol (LAAM) Maintenance Strategies for Heroin Dependence

Moukaddam, Nidal; Herin, David V.; Stotts, Angela L.; Dougherty, Anne H.; Green, Charles; Mooney, Marc E; Garcia, Ann; Meisch, Richard A.; Cowan, Katherine; Moeller, F. Gerard; Schmitz, Joy M.; Grabowski, John J.

doi:10.1097/adt.0b013e3181848b04

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings parallel the opiate literature, indicating maximal benefit for agonist‐like medications after several months of administration (e.g., Ref. 160). Nevertheless, it is clear that further investigation is needed to clarify dosing and duration parameters.…”

Section: Treatment Strategy For Agonist Regimenssupporting

confidence: 86%

Agonist‐like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies

Herin

Rush

Grabowski

2010

Annals of the New York Academy of Sciences

Self Cite

105

View full text Add to dashboard Cite

A variety of natural and synthetic agents have long been used for stimulant properties, with nontherapeutic use producing multiple waves of stimulant abuse and dependence. The multitude of effects of stimulants exist on continua, and accordingly, here we characterize stimulant abuse/dependence and candidate pharmacotherapies in this manner. Behavioral therapy and medications have been investigated for treatment of stimulant abuse/dependence. Effectiveness of some behavioral interventions has been demonstrated. Most medications studied have been found to lack efficacy. However, an expanding literature supports use of agonist-like medications to treat stimulant abuse/dependence, a strategy effective for nicotine and opiate dependence. The agonist-like conceptualization for stimulant dependence posits that medications with properties similar to that of the abused drug, but possessing lesser abuse liability, will normalize neurochemistry and stabilize behavior, thus reducing drug use. Data suggest use of a range of medications, from l-dopa/carbidopa to amphetamine preparations, depending on the severity of use. This report reviews preclinical, human laboratory, and clinical trial data supporting the agonist-like approach, including risks and benefits. Future directions for development of agonist-like medications are also discussed.

show abstract

Section: Treatment Strategy For Agonist Regimenssupporting

confidence: 86%